Education 【 display / non-display 】

Education 【 display / non-display 】

• 2009

  -

  2013

  Sapporo Medical University   Graduate School of Medicine   外科腫瘍学・消化器外科治療学  

• 1999

  -

  2005

  Sapporo Medical University   医学部   医学科  

Degree 【 display / non-display 】

Degree 【 display / non-display 】

• 2013.03   Sapporo Medical University   M.D. and Ph.D.

Research Experience 【 display / non-display 】

Research Experience 【 display / non-display 】

• 2025.07

  -

  Now

  Sapporo Medical University   Department of Pathology   Assistant Professor/Lecturer

• 2020.02

  -

  2025.06

  Sapporo Medical University   Department of Pathology   Assistant professor

• 2019.04

  -

  2020.01

  Sapporo Medical University   Department of Surgery, Surcial Oncology and Science   Clinical Associate

• 2018.12

  -

  2019.03

  Sapporo Medical University   Department of Surgery, Surgical Oncology and Science   Clinical Fellow

• 2016.09

  -

  2018.11

  Heidelberg University Hospital   General, Visceral and Transplantation Surgery, Section Surgical Research   Visiting Research Scholar

display all >>

Professional Memberships 【 display / non-display 】

Professional Memberships 【 display / non-display 】

• 2024

  -

  Now

  日本臨床細胞学会

• 2023

  -

  Now

  The Japanese Society for Clinical Molecular Morphology

• 　

  　

  　

  日本消化器外科学会

• 　

  　

  　

  日本病理学会

• 　

  　

  　

  日本外科学会

display all >>

Research Areas 【 display / non-display 】

Research Areas 【 display / non-display 】

• Life sciences   Digestive surgery  

• Life sciences   Tumor diagnostics and therapeutics  

• Life sciences   Experimental pathology  

• Life sciences   General surgery, pediatric surgery  

• Life sciences   Molecular biology  

Affiliation 【 display / non-display 】

Affiliation 【 display / non-display 】

• Sapporo Medical University   Department of Pathology   Assistant Professor/Lecturer  

Papers 【 display / non-display 】

Papers 【 display / non-display 】

• Concordance of claudin-18.2 expression in biopsy, resection, and recurrent specimens: implications for zolbetuximab therapy in pancreatic ductal adenocarcinoma

  Daisuke Kyuno, Kazuhiko Yanazume, Akira C. Saito, Yusuke Ono, Tatsuya Ito, Masafumi Imamura, Makoto Osanai

  Tissue Barriers    2025.07

  DOI

• Preventive effect of jejunal limb decompression on early-onset postoperative cholangitis following pancreaticoduodenectomy: A propensity score-matched study.

  Kazuharu Kukita, Masafumi Imamura, Eiji Yoshida, Toru Kato, Takeshi Murakami, Daisuke Kyuno, Masayuki Koyama, Yasutoshi Kimura

  Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract     102143 - 102143  2025.07  [International journal]

  　View Summary

  BACKGROUND: Jejunal limb peristalsis may affect recovery at reconstructed sites following pancreato-biliary reconstruction in pancreaticoduodenectomy. This study aimed to investigate the impact of jejunal limb peristalsis on early-onset postoperative cholangitis and evaluate the effectiveness of jejunal limb decompression in its prevention. METHODS: A modified Child's reconstruction was performed during pancreaticoduodenectomy in 281 patients. Patients were divided into jejunal limb decompression (n=210) and non- jejunal limb decompression (n=71) groups based on the placement of a jejunal limb decompression tube. In the decompression group, the relationship between drainage volume of decompression, a potential surrogate for jejunal limb peristalsis, and early-onset postoperative cholangitis was analyzed. Postoperative outcomes were compared between the two groups using propensity score matching. RESULTS: In the jejunal limb decompression group, drainage volume was significantly higher in cases with early-onset postoperative cholangitis compared to those without (770mL [280-1,710mL] vs. 3,330mL [1,355-7,135mL], P<.001). Multivariate analysis identified a drainage volume ≥1,555mL within 14 days post-pancreaticoduodenectomy as an independent risk factor for early-onset postoperative cholangitis (odds ratio: 4.91, 95% confidence interval, 2.18-11.10, P<.001). After propensity score matching, the incidence of early-onset postoperative cholangitis was significantly lower in the decompression group than in the non-decompression group (1.7% vs. 20.7%, P<.003). CONCLUSION: Impaired jejunal limb peristalsis following pancreaticoduodenectomy may be associated with the development of early-onset postoperative cholangitis. The incidence of early-onset postoperative cholangitis is reduced by placement of a jejunal limb decompression tube. DATA SHARING: Data supporting the findings of this study are available upon request from the corresponding author.

  DOI PubMed

• SARS-CoV-2 infection promotes lung thrombosis by inducing integrinβ3 expression in vascular endothelial cells.

  Wataru Ito, Yuya Sakurai, Nako Maishi, Ryo Takeda, Takahito Teshirogi, Li Yu, Yasuhiro Hida, Michihito Sasaki, Yasuko Orba, Takuya Tsumita, Haruhisa Watanabe, Tadahiro Iimura, Terufumi Kubo, Shinsuke Toba, Akihiko Sato, Aya Matsuda, Daisuke Kyuno, Makoto Osanai, Yoichi Ohiro, Toshihiko Torigoe, Hirofumi Sawa, Kyoko Hida

  Scientific reports   15 ( 1 ) 20447 - 20447  2025.07  [International journal]

  　View Summary

  Severe COVID-19 shows a high incidence of pulmonary thrombosis. However, the molecular mechanism underlying this phenomenon remains unclear. We have performed RNA sequencing of isolated endothelial cells (ECs) from infected mid-aged and young mice. Compared to young mice, Integrinβ3 (ITGB3) expression levels were higher in ECs of mid-aged mice which showed thrombosis in lungs. SARS-CoV-2 exposure increased the number of adhered platelets on the EC monolayer in vitro. Knockdown of ITGB3 in ECs decreased platelet adhesion to them. Among the molecules known as SARS-CoV-2 receptors, Kringle-containing transmembrane protein 1 contributed to ITGB3 upregulation in ECs by SARS-CoV-2. Histological analysis showed that ITGB3-positive blood vessels were frequently detected not only in infected-mid-aged mouse lungs but also in COVID-19-affected human autopsy lungs. This study suggests that the induction of ITGB3 expression in ECs is one of the mechanisms of thrombosis in severe COVID-19 pneumonia.

  DOI PubMed

• Contrast-Enhanced Ultrasound Predicts Surgical Margin Positivity in Patients With Breast Cancer Who Underwent Partial Mastectomy.

  Hiroaki Shima, Fukino Satomi, Daisuke Kyuno, Noriko Nishikawa, Satoko Uno, Yuta Kondo, Ai Noda, Takashi Nakamura, Toru Mizuguchi

  World journal of surgery    2025.05  [International journal]

  　View Summary

  BACKGROUND: The clinical disadvantage of positive margins in partial mastectomy for patients with operable breast cancer is clear and must be avoided; however, there is still room for improvement. The usefulness of contrast-enhanced ultrasound (CEUS) in diagnosing spread is currently well-known. The CEUS-enhanced area for breast cancer tends to be wider than that observed in B-mode US and probably includes cancer cells. Therefore, we focused on the difference obtained by subtracting the maximum diameter on B-mode US from that on CEUS. This parameter tends to be greater than zero. However, there are tricky cases in which such enhancements are not visible, and the enhanced area remains limited to a small region. This study aimed to analyze the correlation between characteristic findings and positive for margins in order to ultimately prove potential usefulness of CEUS in making the surgical margin negative. METHODS: We retrospectively evaluated the data of consecutive 142 patients with breast cancer who underwent partial mastectomy to explore the effect on positive margins when the CEUS enhancing area was smaller than the B-mode US visualized mass (CEUS-B ≤ 0). RESULTS: Positive surgical margins were observed in 14 out of 142 patients. CEUS-B ≤ 0 was associated with significantly more positive margins (p = 0.0467). CEUS-B was also extracted as an independent predictor on multivariate analysis. CONCLUSIONS: The findings of no enhancement outside the area of visible tumor on CEUS but not visualized outside the area of visible tumor on B-mode US might be a risk factor for a positive surgical margin.

  DOI PubMed

• The Role of Claudin-1 in Enhancing Pancreatic Cancer Aggressiveness and Drug Resistance via Metabolic Pathway Modulation

  Daisuke Kyuno, Hinae Asano, Reona Okumura, Kumi Takasawa, Akira Takasawa, Takumi Konno, Yuna Nakamori, Kazufumi Magara, Yusuke Ono, Masafumi Imamura, Yasutoshi Kimura, Takashi Kojima, Makoto Osanai

  Cancers   17 ( 9 )  2025.04  [International journal]

  　View Summary

  BACKGROUND/OBJECTIVES: Pancreatic ductal adenocarcinoma is a lethal malignancy, necessitating an understanding of its molecular mechanisms for the development of new therapeutic strategies. The tight junction protein claudin-1, known to influence cellular functions in various cancers and is considered a therapeutic target, remains unclear in pancreatic cancer. METHODS: This study assessed claudin-1 expression in resected pancreatic cancer samples, public databases, and pancreatic cancer cell lines. Claudin-1 knockout with CRISPR/Cas9 on poorly differentiated pancreatic cancer cell lines and a proteome analysis were performed to investigate the intracellular mechanisms of claudin-1. RESULTS: Claudin-1 was markedly overexpressed in pancreatic ductal adenocarcinoma and intraepithelial neoplasia compared to normal ducts, and high claudin-1 levels were an independent predictor of poor prognosis. Claudin-1 knockout diminished cell proliferation, migration, invasion, and chemoresistance in pancreatic ductal adenocarcinoma. Proteome analysis revealed the significant downregulation of aldo-keto reductase family proteins (AKR1C2, AKR1C3, and AKR1B1) in claudin-1 knockout cells, which are linked to metabolic pathways. Aldo-keto reductase knockdown reduced chemoresistance, proliferation, and invasion in these cell lines. CONCLUSIONS: These findings indicate that the abnormal expression of claudin-1 promotes tumor progression and drug resistance through its interaction with aldo-keto reductase proteins, highlighting claudin-1 and aldo-keto reductase family proteins as potential biomarkers and therapeutic targets for pancreatic cancer.

  DOI PubMed

display all >>

Books and Other Publications 【 display / non-display 】

Books and Other Publications 【 display / non-display 】

• インフォームドコンセントのための図説シリーズ 膵がん 改訂3版

  ( Part： Contributor, 術後のフォローアップの方法)

Misc 【 display / non-display 】

Misc 【 display / non-display 】

• 膵癌患者の予後と癌進展におけるJAM-Aの役割(Junctional Adhesion Molecule-A may play a role in the progression of pancreatic cancer)

  及能 大輔, 高澤 啓, 高澤 久美, 真柄 和史, 小山内 誠

  日本癌学会総会記事 ( (一社)日本癌学会 )  81回   J - 2053  2022.09

• 膵癌がんで高発現する解糖系酵素ALDOAはがん悪性化に関与する(Glycolytic enzyme ALDOA, highly expressed in pancreatic cancer, is involved in malignant potentials)

  高澤 啓, 高澤 久美, 真柄 和史, 及能 大輔, 後藤 正憲, 田中 宏樹, 藤井 裕美子, 小山内 誠

  日本癌学会総会記事 ( (一社)日本癌学会 )  83回   P - 2285  2024.09

• 肺多形癌における癌免疫微小環境の組織学的解析(A Histological evaluation of immune microenvironment in pulmonary pleomorphic carcinoma)

  多田 聡法, 廣橋 良彦, 高澤 久美, 真柄 和史, 及能 大輔, 長谷川 匡, 小山内 誠, 高澤 啓, 高澤 久美

  日本癌学会総会記事 ( (一社)日本癌学会 )  83回   P - 1176  2024.09

• 膵癌におけるClaudin 1の機能と予後に与える影響(The Role of Claudin 1 in Pancreatic Cancer Progression: A Study of Expression and Prognosis)

  及能 大輔, 浅野 日南英, 奥村 礼央菜, 真柄 和史, 小野 佑輔, 今村 将史, 高澤 久美, 竹政 伊知朗, 高澤 啓, 小山内 誠

  日本癌学会総会記事 ( (一社)日本癌学会 )  83回   J - 2051  2024.09

• MPNSTで異常高発現するPVRはがん悪性化に寄与し,治療標的となりうる

  中橋 尚也, 高澤 啓, 江森 誠人, 高澤 久美, 真柄 和史, 小野 佑輔, 及能 大輔, 杉田 真太朗, 長谷川 匡, 小山内 誠, 寺本 篤史

  日本整形外科学会雑誌 ( (公社)日本整形外科学会 )  98 ( 8 ) S1750 - S1750  2024.09

display all >>

Awards 【 display / non-display 】

Awards 【 display / non-display 】

• Sapporo Medical University Grants for Programs promoting Academic advancements

  2025.06   Sapporo Medical University   膵癌の進展を促進するタイト結合分子の同定とその機序の解明

• Research grant

  2024   THE SUHARA MEMPRIAL FOUNDATION   膵癌の予後不良サブタイプにおけるタイト結合分子の機能解析と新規治療法を開発するための基盤的研究

• 膵臓病研究奨励賞

  2022   日本膵臓病研究財団   タイト結合分子により促進される膵癌の進展機序の解明

• Young investigator award

  2019.11   Japanese digestive disease week   Exosomes transfer information of cancer cells; reprogramming of nonmetastasizing tumor cells and therapeutic efficacy

  Winner： Daisuke Kyuno

• Young Investigator Award

  2015   国際外科学会日本部会  

  Winner： 及能大輔

display all >>

Research Projects 【 display / non-display 】

Research Projects 【 display / non-display 】

• 膵癌の予後不良サブタイプにおけるタイト結合分子の機能解析と新規治療法を開発するための基盤的研究

  Project Year :

  2025

  -

  2026

   

  Authorship： Principal investigator

• 膵癌の予後不良群に過剰発現するタイト結合分子が促進する癌進展機構の解明

  基盤研究(C)

  Project Year :

  2024.04

  -

  2027.03

   

  及能大輔、今村将史、木村康利、髙澤啓

  Authorship： Principal investigator

• 遺伝子プロファイルとctDNAに基づくサブタイプ別膵癌精密医療実装のための探索的研究

  基盤研究(C)

  Project Year :

  2023.04

  -

  2026.03

   

  木村 康利, 今村 将史, 竹政 伊知朗, 村上 武志, 久木田 和晴, 及能 大輔

• Development of a novel biomarker for postoperative early recurrence of pancreatic cancer by sequential analysis of exosomal miRNAs

  Grant-in-Aid for Scientific Research (C)

  Project Year :

  2023.04

  -

  2026.03

   

  今村 将史, 木村 康利, 永山 稔, 及能 大輔, 久木田 和晴, 村上 武志, 竹政 伊知朗

• イムノヒストグラムを用いた直腸癌に対する術前化学療法の新規治療効果予測法の開発

  基盤研究(C)

  Project Year :

  2022.04

  -

  2025.03

   

  奥谷 浩一, 秋月 恵美, 廣橋 良彦, 竹政 伊知朗, 佐藤 雄, 石井 雅之, 浜部 敦史, 沖田 憲司, 及能 大輔

display all >>